Influence of lynch syndrome on the incidence of side effects to antineoplastic treatment of patients with colorectal cancer.

To analyze the influence of Lynch Syndrome on the incidence of adverse reactions to antineoplastic treatment in patients with colorectal cancer. Observational and retrospective study based on analyzing electronic medical records of patients treated at Hospital Haroldo Juaçaba/Ceará Cancer Institute (HHJ/ICC). Patients with NCCN clinical criteria for Lynch Syndrome and a diagnosis of colorectal cancer were included, comparing the profile of adverse reactions to chemotherapy between those with and without pathogenic mutations associated with the syndrome. The sample consisted of 161 patients with suspected Lynch Syndrome, all undergoing chemotherapy. A higher frequency of adverse reactions was observed among patients without a pathogenic mutation for Lynch Syndrome. Approximately two-thirds of the sample reported adverse reactions, with nausea being the most common adverse event, followed by neurotoxicity and diarrhea. Patients with colorectal cancer without a pathogenic mutation for Lynch syndrome had a higher incidence of adverse reactions to chemotherapy. This finding may be related to biological and physiological factors, including greater cellular variability, the need for more intensive therapeutic regimens, and the influence of individual genetic variability. These results highlight the importance of personalized approaches in managing the side effects of cancer treatment.